Search

Your search keyword '"Rizzari, C."' showing total 161 results
Start Over Author "Rizzari, C." Database OpenAIRE
161 results on '"Rizzari, C."'

1. Incidence and Characteristics of Hypersensitivity Reactions to PEG-asparaginase Observed in 6136 Children with Acute Lymphoblastic Leukemia Enrolled in the AIEOP-BFM ALL 2009 Study Protocol

Author

Rizzari C., Möricke A., Valsecchi M. G., Conter V., Zimmermann M., Silvestri D., Attarbaschi A., Niggli F., Barbaric D., Stary J., Elitzur S., Cario G., Vinti L., Boos J., Zucchetti M., Lanvers-Kaminsky C., Von Stackelberg A., Biondi A., Schrappe M., Rizzari, C, Möricke, A, Valsecchi, M, Conter, V, Zimmermann, M, Silvestri, D, Attarbaschi, A, Niggli, F, Barbaric, D, Stary, J, Elitzur, S, Cario, G, Vinti, L, Boos, J, Zucchetti, M, Lanvers-Kaminsky, C, Von Stackelberg, A, Biondi, A, and Schrappe, M

Subjects
MED/38 - PEDIATRIA GENERALE E SPECIALISTICA, acute lymphoblastic leukemia, childhood, chemoterapy, asparaginase
Abstract

The incidence of hypersensitivity reactions (HSRs) to PEG-asparaginase (PEG-ASNase) was evaluated in 6136 children with ALL enrolled in the AIEOP-BFM ALL 2009 study. Patients with B-cell precursor-acute lymphoblastic leukemia (BCP-ALL) were stratified as standard-risk/medium-risk (MR)/high-risk (HR) and those with T-ALL as non-High/HR. PEG-ASNase was administered intravenously at 2500 IU/sqm/dose. All patients received 2 PEG-ASNase doses in induction; thereafter non-HR versus HR patients received 1 versus 6 PEG-ASNase doses, respectively. After the single regular dose of PEG-ASNase at the beginning of delayed intensification, BCP-ALL-MR patients were randomized to receive 9 additional PEG-ASNase doses every 2 weeks (experimental arm [EA]) versus none (standard arm [SA]); HR patients were randomized to receive, in consolidation, 4 weekly PEG-ASNase doses (EA) versus none (SA). The HSR cumulative incidence (CI) was estimated adjusting for competing risks. An HSR occurred in 472 of 6136 (7.7%) patients. T-non- HR/BCP-Standard-Risk, BCP-MR-SA, BCP-MR-EA, HR-SA and HR-EA patients had 1-year-CI-HSR (±SE) rates of 5.2% (0.5), 5.2% (0.5), 4.0% (0.8), 20.2% (1.2), and 6.4% (1.3), respectively. The randomized intensification of PEG-ASNase did not significantly impact on HSR incidence in BCP-MR patients (1-y-CI-HSR 3.8% [0.8] versus 3.2% [0.6] in MR-EA versus MR-SA; P = 0.55), while impacted significantly in HR patients (1-y-CI-HSR 6.4% [1.3] versus 17.9% [1.8] in HR-EA and HR-SA, respectively; P < 0.001). The CI-HSR was comparable among non-HR groups and was not increased by a substantial intensification of PEG-ASNase in the BCP-MR-EA group whilst it was markedly higher in HR-SA than in HR-EA patients, suggesting that, in such a chemotherapy context, a continuous exposure to PEG-ASNase reduces the risk of developing an HSR.

Published
2023

2. Hypersensitivity Reactions to Native E. coli L-asparaginase in Children with Acute Lymphoblastic Leukemia Treated in Trial ALL-BFM 2000: Impact of Treatment Schedule and Type of Glucocorticoid in Induction

Author

Moricke A., Rizzari C., Alten J., Attarbaschi A., Beier R., Biondi A., Burkhardt B., Bodmer N., Boos J., Cario G., Conter V., Flotho C., Kulozik A., Lanvers-Kaminsky C., Mann G., Niggli F., Silvestri D., Von Stackelberg A., Stanulla M., Valsecchi MG., Schrappe M., Zimmermann M., Moricke, A, Rizzari, C, Alten, J, Attarbaschi, A, Beier, R, Biondi, A, Burkhardt, B, Bodmer, N, Boos, J, Cario, G, Conter, V, Flotho, C, Kulozik, A, Lanvers-Kaminsky, C, Mann, G, Niggli, F, Silvestri, D, Von Stackelberg, A, Stanulla, M, Valsecchi, M, Schrappe, M, and Zimmermann, M

Subjects
acute lymphoblastic leukemia, immunotherapy, MED/38 - PEDIATRIA GENERALE E SPECIALISTICA, chemotherapy, childhood
Published
2023

3. Challenging Management of Severe Differentiation Syndrome in Pediatric Acute Promyelocytic Leukemia Treated with ATRA/ATO

Author

Molinaro A., Zanta D., Moleti M. L., Giona F., Conter V., Rizzari C., Biondi A., Testi A. M., Molinaro, A, Zanta, D, Moleti, M, Giona, F, Conter, V, Rizzari, C, Biondi, A, and Testi, A

Subjects
Infectious Diseases, Differentiation Syndrome, ATRA/ATO combination, Acute Promyelocytic Leukemia, Hematology, Children
Abstract

The ATRA/ATO combination treatment of acute promyelocytic leukemia (APL) represents a paradigm of successful targeted and chemotherapy-free treatment in oncology. This therapeutic strategy is aimed at sparing patients from chemotherapy toxicity, while maintaining an excellent survival with a low risk of relapse. Main induction treatment-related complications are differentiation syndrome (DS) and hyperleukocytosis, which is related to DS and its severity. In the period December 2019 – December 2020, 8 children with newly diagnosed APL underwent induction therapy with ATRA/ATO in our center. In patients with WBC≥10x109/L two doses of Gemtuzumab Ozogamicin (GO) were added. In case of severe DS or hyperleukocytosis the differentiating agents were discontinued, high dose dexamethasone (DXM) and/or hydroxyurea (HU) were recommended. Five patients presented WBC

Published
2021

4. CD56, HLA-DR, and CD45 recognize a subtype of childhood AML harboring CBFA2T3-GLIS2 fusion transcript

Author

Zangrando, A., Cavagnero, F., Scarparo, P., Varotto, E., Francescato, S., Tregnago, C., Cuccurullo, R., Fagioli, F., Nigro, L. L., Masetti, R., Putti, M. C., Rizzari, C., Santoro, N., Pession, A., Pigazzi, M., Locatelli, F., Basso, G., Buldini, B., Zangrando, A, Cavagnero, F, Scarparo, P, Varotto, E, Francescato, S, Tregnago, C, Cuccurullo, R, Fagioli, F, Nigro, L, Masetti, R, Putti, M, Rizzari, C, Santoro, N, Pession, A, Pigazzi, M, Locatelli, F, Basso, G, Buldini, B, Zangrando A., Cavagnero F., Scarparo P., Varotto E., Francescato S., Tregnago C., Cuccurullo R., Fagioli F., Nigro L.L., Masetti R., Putti M.C., Rizzari C., Santoro N., Pession A., Pigazzi M., Locatelli F., Basso G., and Buldini B.

Subjects
Oncogene Proteins, Fusion, Brief Report, HLA-DR Antigens, acute myeloid leukemia, Repressor Proteins, CBFA2T3‐GLIS2, Leukemia, Myeloid, Acute, computational analysi, Settore MED/38 - PEDIATRIA GENERALE E SPECIALISTICA, immunophenotyping, computational analysis, hemic and lymphatic diseases, Humans, CBFA2T3-GLIS2, Child, Transcriptome
Abstract

The presence of CBFA2T3‐GLIS2 fusion gene has been identified in childhood Acute Myeloid Leukemia (AML). In view of the genomic studies indicating a distinct gene expression profile, we evaluated the role of immunophenotyping in characterizing a rare subtype of AML‐CBFA2T3‐GLIS2 rearranged. Immunophenotypic data were obtained by studying a cohort of 20 pediatric CBFA2T3‐GLIS2‐AML and 77 AML patients not carrying the fusion transcript. Enrolled cases were included in the Associazione Italiana di Ematologia Oncologia Pediatrica (AIEOP) AML trials and immunophenotypes were compared using different statistical approaches. By multiple computational procedures, we identified two main core antigens responsible for the identification of the CBFA2T3‐GLIS2‐AML. CD56 showed the highest performance in single marker evaluation (AUC = 0.89) and granted the most accurate prediction when used in combination with HLA‐DR (AUC = 0.97) displaying a 93% sensitivity and 99% specificity. We also observed a weak‐to‐negative CD45 expression, being exceptional in AML. We here provide evidence that the combination of HLA‐DR negativity and intense bright CD56 expression detects a rare and aggressive pediatric AML genetic lesion improving the diagnosis performance.

Published
2021

5. Legionellosis in paediatrics [Legionellosi in pediatria]

Author

Impagnatiello L., Bersanini C., Spinelli M., Ferrari G. M., Biondi A., Rizzari C., Impagnatiello, L, Bersanini, C, Spinelli, M, Ferrari, G, Biondi, A, and Rizzari, C

Subjects
Pneumonia, Immunodepression, Legionella pneumophila
Published
2020

6. Complicanze infettive gravi nei pazienti affetti da leucemia linfoblastica acuta (LLA) arruolati nel protocollo AIEOP-BFM ALL 2009: incidenza ed esito. Hematology Reports 2018; 10 (s1): 67

Author

Colombini, A., Brivio, E., Barisone, E., Barone, A., Cellini, M., Kiren, V., La-Spina, M., Mina, T., Muggeo, P., Mura, R., Parasole, R., Putti, M. C., Rizzari, C., Silvestri, D., Vinti, L., Conter, V., and Cesaro, S.

Subjects
leucemia linfoblastica acuta, pediatria, infezioni batteriche, leucemia linfoblastica acuta, pediatria, infezioni batteriche
Published
2018

7. Results of the AIEOP AML 2002/01 multicenter prospective trial for the treatment of children with acute myeloid leukemia

Author

Pession A, Masetti R, Rizzari C, Putti MC, Fagioli F, Luciani M, Lo Nigro L, Menna G, Micalizzi C, Santoro N, Testi AM, Zecca M, Biondi A, Pigazzi M, Rutella S, Rondelli R, Basso G, Locatelli F, AIEOP AML Study Group, CASALE, Fiorina, Pession, A, Masetti, R, Rizzari, C, Putti, Mc, Casale, Fiorina, Fagioli, F, Luciani, M, Lo Nigro, L, Menna, G, Micalizzi, C, Santoro, N, Testi, Am, Zecca, M, Biondi, A, Pigazzi, M, Rutella, S, Rondelli, R, Basso, G, Locatelli, F, AIEOP AML Study, Group, Pession A, Masetti R, Rizzari C, Putti MC, Casale F, Fagioli F, Luciani M, Lo Nigro L, Menna G, Micalizzi C, Santoro N, Testi AM, Zecca M, Biondi A, Pigazzi M, Rutella S, Rondelli R, Basso G, Locatelli F, Putti, M, Casale, F, Testi, A, and AIEOP AML Study, G

Subjects
Oncology, Myeloid, Male, Pediatrics, medicine.medical_treatment, Hematopoietic stem cell transplantation, Biochemistry, Recurrence, hemic and lymphatic diseases, Antineoplastic Combined Chemotherapy Protocols, Child, PEDIATRIC AML, Leukemia, ACUTE MYELOGENOUS LEUKEMIA, Hematopoietic Stem Cell Transplantation, Myeloid leukemia, Induction Chemotherapy, Hematology, HIGH-DOSE CYTARABINE, Leukemia, Myeloid, Acute, medicine.anatomical_structure, Treatment Outcome, N/A, Settore MED/38 - PEDIATRIA GENERALE E SPECIALISTICA, Child, Preschool, Female, Autologous, Homologous, medicine.medical_specialty, Adolescent, Immunology, Acute, Transplantation, Autologous, AIEOP, children, acute myeloid leukemia, Internal medicine, medicine, Transplantation, Homologous, Autologous transplantation, Humans, Preschool, Transplantation, business.industry, Infant, Newborn, Induction chemotherapy, Infant, Cell Biology, medicine.disease, Newborn, BONE-MARROW-TRANSPLANTATION, INTENSIVE CHEMOTHERAPY, Consolidation Chemotherapy, Follow-Up Studies, Prospective trial, business
Abstract

We evaluated the outcome of 482 children with acute myeloid leukemia (AML) enrolled in the Associazione Italiana di Ematologia e Oncologia Pediatrica AML 2002/01 trial. Treatment was stratified according to risk group; hematopoietic stem cell transplantation (HSCT) was used in high-risk (HR) children. Patients with core binding factor leukemia achieving complete remission (CR) after the first induction course were considered standard risk (SR; 99 patients), whereas the others (n 5 383) were assigned to the HR group. Allogeneic (ALLO) or autologous (AUTO) HSCT was employed, respectively, in 141 and 102 HR patients after consolidation therapy. CR, early death, and induction failure rates were 87%, 3%, and 10%, respectively. Relapse occurred in 24%of patients achieving CR. The 8-year overall survival (OS), event-free survival (EFS), and disease-free survival (DFS) were 68%, 55%, and 63%, respectively. OS, EFS, and DFS for SR and HR patients were 83%, 63%, and 66% and 64%, 53%, and 62%. DFS was 63% and 73% for HR patients given AUTO-HSCT and ALLO-HSCT, respectively. In multivariate analysis, risk group, white blood cell >100 × 109/L at diagnosis, and monosomal karyotype predicted poorer EFS. Risk-oriented treatment and broad use of HSCT result in a long-term EFS comparing favorably with previously published studies on childhood AML. (Blood. 2013; 122(2):170-178) © 2013 by The American Society of Hematology.

Published
2013

8. Air pollution and childhood leukaemia: a nationwide case-control study in Italy

Author

Badaloni, C., Ranucci, A., Cesaroni, G., Zanini, G., Vienneau, D., Al Aidrous, F., De Hoogh, K., Magnani, C., Forastiere, F., Mattioli, Stefano, Miligi, L., Rondelli, R., Salvan, A., Masera, G., Rizzari, C., Bisanti, L., Zambon, P., Greco, A., Cannizzaro, S., Gafa, L., Luzzatto, L. L., Benvenuti, A., Michelozzi, P., Kirchmayer, U., Cocco, P., Galassi, C., Celentano, E., Guarino, E., Assennato, G., de Nichilo, G., Merlo, D. F., Bocchini, V., Mosciatti, P., Minelli, L., Chiavarini, M., Cuttini, M., Casotto, V., Torregrossa, M. V., Valenti, R. M., Haupt, R., Lagorio, S., Risica, S., Polichetti, A., Bochicchio, F., Nuccetelli, C., Biddau, P., Arico, M., De Salvo, G. L., Locatelli, F., Pession, Andrea, Varotto, S., Poggi, V., Massaglia, P., Monetti, D., Targhetta, R., Bernini, G., Pannelli, F., Sampietro, G., Schiliro, G., Pulsoni, A., Badaloni, C., Ranucci, A., Cesaroni, G., Zanini, G., Vienneau, D., Al-Aidrous, F., De Hoogh, K., Magnani, C., Forastiere, F., C. Badaloni, A. Ranucci, G. Cesaroni, G. Zanini, D. Vienneau, F. Al-Aidrou, K. De Hoogh, C. Magnani, F. Forastiere, S. Mattioli, L. Miligi, R. Rondelli, A. Salvan, G. Masera, C. Rizzari, L. Bisanti, P. Zambon, A. Greco, S. Cannizzaro, L. Gafa, L. L. Luzzatto, A. Benvenuti, P. Michelozzi, U. Kirchmayer, P. Cocco, C. Galassi, E. Celentano, E. Guarino, G. Assennato, G. de Nichilo, D. F. Merlo, V. Bocchini, P. Mosciatti, L. Minelli, M. Chiavarini, M. Cuttini, V. Casotto, M. V. Torregrossa, R. M. Valenti, R. Haupt, S. Lagorio, S. Risica, A. Polichetti, F. Bochicchio, C. Nuccetelli, P. Biddau, M. Arico, G. L. De Salvo, F. Locatelli, A. Pession, S. Varotto, V. Poggi, P. Massaglia, D. Monetti, R. Targhetta, G. Bernini, F. Pannelli, G. Sampietro, G. Schiliro, and A. Pulsoni

Subjects
Male, Pediatrics, Air pollution, NO2, Land use Regression Model, Logistic regression, medicine.disease_cause, Economica, Residence Characteristics, USE REGRESSION-MODELS, Medicine, Child, Children, Vehicle Emissions, General Environmental Science, USE REGRESSION-MODELS, RESIDENTIAL TRAFFIC DENSITY, MAGNETIC-FIELDS, POOLED ANALYSIS, RISK-FACTOR, CANCER, EXPOSURE, CHILDREN, NO2, ASSOCIATION, Leukemia, Incidence, Incidence (epidemiology), ASSOCIATION, CANCER, Childhood leukaemia, Italy, Child, Preschool, Female, Case-Control Studie, Human, medicine.medical_specialty, Socio-culturale, MAGNETIC-FIELDS, POOLED ANALYSIS, RISK-FACTOR, Air Pollution, Occupational Exposure, Environmental health, Traffic Indicator, Humans, EXPOSURE, RESIDENTIAL TRAFFIC DENSITY, Exposure assessment, Vehicle Emission, business.industry, Public Health, Environmental and Occupational Health, Case-control study, Ambientale, Infant, Carcinogens, Environmental, Automobile, Case-Control Studies, Residence Characteristic, Dispersion Model, Etiology, General Earth and Planetary Sciences, Particulate Matter, Residence, business, Automobiles
Abstract

Objectives Leukaemia is the most common cancer in children, but its aetiology is still poorly understood. We tested the hypothesis that traffic-related air pollution is associated with paediatric leukaemia because of chronic exposure to several potential carcinogens. Methods The Italian SETIL study (Study on the aetiology of lymphohematopoietic malignancies in children) was conducted in 14 Italian regions. All incident cases of leukaemia in children aged ≤10 years from these regions (period 1998–2001) were eligible for enrolment. Two controls per case, matched on birth date, gender and region of residence were randomly selected from the local population registries. Exposure assessment at birth residence included traffic indicators (distance to main roads and length of main roads within 100 m) and estimates of pollutants concentrations (particulate matter -PM 2.5 and PM 10 - and gases -NO 2 and O 3 -) from national dispersion model and land use regression models. The association between the exposure variables and leukaemia was assessed by logistic regression analyses. Results Participation rates were 91.4% among cases and 69.2% in controls; 620 cases (544 acute lymphocytic and 76 acute non-lymphocytic leukaemia) and 957 controls were included. Overall, when considering the residence at birth, 35.6% of cases and 42.4% of controls lived along busy roads, and the mean annual PM 10 levels were 33.3 (SD=6.3) and 33.4 µg/m 3 (SD=6.5), respectively. No association was found, and all ORs, independent of the method of assessment and the exposure windows, were close to the null value. Conclusions Using various exposure assessment strategies, air pollution appears not to affect the incidence of childhood leukaemia.

Published
2013

9. Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) Studies 82, 87, 88, 91 and 95 for childhood acute lymphoblastic leukemia

Author

Conter V., Aricò M., Basso G., Biondi A., Barisone E., Messina C., Parasole R., De Rossi G., Locatelli F., Santoro N., Micalizzi C., Citterio M., Rizzari C., Silvestri D., Rondelli R., Lo Nigro L., Ziino O., Testi A.M., Masera G., Valsecchi M.G., Associazione Italiana di Ematologia ed Oncologia Pediatrica, PESSION, ANDREA, Conter V., Aricò M., Basso G., Biondi A., Barisone E., Messina C., Parasole R., De Rossi G., Locatelli F., Pession A., Santoro N., Micalizzi C., Citterio M., Rizzari C., Silvestri D., Rondelli R., Lo Nigro L., Ziino O., Testi AM., Masera G., Valsecchi MG., Associazione Italiana di Ematologia ed Oncologia Pediatrica., Conter, V, Aricò, M, Basso, G, Biondi, A, Barisone, E, Messina, C, Parasole, R, De Rossi, G, Locatelli, F, Pession, A, Santoro, N, Micalizzi, C, Citterio, M, Rizzari, C, Silvestri, D, Rondelli, R, Lo Nigro, L, Ziino, O, Testi, A, Masera, G, and Valsecchi, M

Subjects
Male, Oncology, Cancer Research, medicine.medical_specialty, Pediatrics, acute lymphoblastic leukemia, childhood, long-term results, Time Factors, Adolescent, Time Factor, Prognosi, Medical Oncology, Systemic therapy, Follow-Up Studie, Risk Factors, Internal medicine, Acute lymphocytic leukemia, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Child, Survival rate, Childhood Acute Lymphoblastic Leukemia, Antineoplastic Combined Chemotherapy Protocol, Hematology, business.industry, Risk Factor, Remission Induction, Infant, Cancer, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Prognosis, medicine.disease, Minimal residual disease, Survival Rate, Treatment Outcome, Italy, El Niño, Child, Preschool, Female, Cranial Irradiation, business, Follow-Up Studies, Human
Abstract

We analyzed the long-term outcome of 4865 patients treated in Studies 82, 87, 88, 91 and 95 for childhood acute lymphoblastic leukemia (ALL) of the Italian Association of Pediatric Hematology and Oncology (AIEOP). Treatment was characterized by progressive intensification of systemic therapy and reduction of cranial radiotherapy. A progressive improvement of results with reduction of isolated central nervous system relapse rate was obtained. Ten-year event-free survival increased from 53% in Study 82 to 72% in Study 95, whereas survival improved from 64 to 82%. Since 1991, all patients were treated according to Berlin-Frankfurt-Muenster (BFM) ALL treatment strategy. In Study 91, reduced treatment intensity (25%) yielded inferior results, but intensification of maintenance with high-dose (HD)-L-asparaginase (randomized) allowed to compensate for this disadvantage; in high-risk patients (HR, 15%), substitution of intensive polychemotherapy blocks for conventional BFM backbone failed to improve results. A marked improvement of results was obtained in HR patients when conventional BFM therapy was intensified with three polychemotherapy blocks and double delayed intensification (Study 95). The introduction of minimal residual disease monitoring and evaluation of common randomized questions by AIEOP and BFM groups in the protocol AIEOP-BFM-ALL 2000 are expected to further ameliorate treatment of children with ALL.

Published
2010

10. Italian multicentricepidemiological case control strudy on risk factors for childhood leukemia,non hodgkin limphoma and neuroblastoma:study population and prevalence of risk factors in Italy

Author

Magnani, C, Mattioli, S, Miligi, L, Ranucci, A, Rondelli, R, Salvan, A, Bisanti, L, Masera, G, Rizzari, C, Zambon, P, Cannizzaro, S, Gafà, L, Luzzatto, LL, Benvenuti, A, Michelozzi, P, Kirchmayer, U, Cocco, P, Biddau, P, Galassi, C, Celentano, E, Guarino, E, Assennato, G, Nichilo, GD, Merlo, DF, Bocchini, V, Pannelli, F, Mosciatti, P, Minelli, L, Chiavarini, M, Cuttini, M, Casotto, V, Forastiere, F, Haupt, R, Lagorio, S, Risica, S, Polichetti, A., TORREGROSSA, Maria Valeria, VALENTI, Rosalia Maria, Magnani, C, Mattioli, S, Miligi, L, Ranucci, A, Rondelli, R, Salvan, A, Bisanti, L, Masera, G, Rizzari, C, Zambon, P, Cannizzaro, S, Gafà, L, Luzzatto, LL, Benvenuti, A, Michelozzi, P, Kirchmayer, U, Cocco, P, Biddau, P, Galassi, C, Celentano, E, Guarino, E, Assennato, G, Nichilo, GD, Merlo, DF, Bocchini, V, Pannelli, F, Mosciatti, P, Minelli, L, Chiavarini, M, Cuttini, M, Casotto, V, Torregrossa, MV, Valenti, RM, Forastiere, F, Haupt, R, Lagorio, S, Risica, S, and Polichetti, A

Subjects
Settore MED/42 - Igiene Generale E Applicata, childhood leukemia, childhood neoplasm
Abstract

Background Aetiology of childhood leukaemia and childhood neoplasm is poorly understood. Information on the prevalence of risk factors in the childhood population is limited. SETIL is a population based case/control study on childhood leukaemia, conducted with two companion studies on non-Hodgkin Lymphoma (NHL) and neuroblastoma. The study relies on questionnaire interviews and 50 Hz magnetic field (ELF-MF) indoor measurements. This paper discusses the SETIL study design and includes descriptive information. Methods The study was carried out in 14 Italian regions (78.3% of Italian population aged 0?10). It included leukaemia, NHL and neuroblastoma cases incident in 0?10 year olds in 1998-2001,registered by the Italian Association of Paediatric Haematology and Oncology (AIEOP)(accrual over 95% of estimated incidence). Two controls for each leukaemia case were randomly sampled from the Local Health Authorities rolls, matched by gender, birthdate and residence. The same controls were used in NHL and neuroblastoma studies. Parents were interviewed at home on: physical agents (ELF-MF and ionizing radiation), chemicals (smoking, solvents, traffic, insecticides), occupation, medical and personal history of children and parents, infectious diseases, immunizations and associated factors. Occupational exposure was collected using job specific modules. ELF-MF was measured in the main rooms (spot measurement) and close to child?s bed (48 hours measurement). Results The study included: 683 leukaemia cases (87% ALL, 13% AnLL), 97 NHL, 155 neuroblastomas, and 1044 controls.ELF-MF long term measurements were obtained for 61.1% of controls and 81.6% of leukaemia cases; 8.8% of controls were exposed at over 0.1 microTesla (μT), 3.5% and 2.1% at respectively over 0.2 and 0.3 μT. 25% of controls? fathers had smoked over 10 cigarettes/day during the year of conception, varying according to education and region. Maternal smoking was less common (71.4% did not smoke in pregnancy). Maternal passive smoking during pregnancy was reported by 31.2% of controls; the child?s passive smoking for 28.6%. Occupational exposure to solvents was estimated in 18.3% of controls? fathers and 7.7% of mothers. Contact with public was more frequent among mothers (36.1%) than fathers (23.4%). Conclusions SETIL represents a data source on exposure of Italian children to a broad array of potential carcinogenic factors.

Published
2014

11. Risk of neuroblastoma, maternal characteristics and perinatal exposures: the SETIL study

Author

Parodi S, Merlo DF, Ranucci A, Miligi L, Benvenuti A, Rondelli R, Magnani C, Haupt R, Mattioli S, Salvan A, Masera G, Rizzari C, Bisanti L, Zambon P, Greco Veneto A, Cannizzaro S, Gafà L, Luzzatto LL, Michelozzi P, Kirchmayer U, Cocco P, Galassi C, Celentano E, Guarino E, Assennato G, de Nichilo G, Bocchini V, Mosciatti P, Pubblica S, Minelli L, Chiavarini M, Cuttini M, Casotto V, Torregrossa MV, Valenti RM, Forastiere F, Lagorio S, Risica S, Polichetti A, Bochicchio F, Nuccetelli C, Biddau P, Aricò M, DeSalvo GL, Locatelli F, Pession A, Varotto S, Poggi V, Massaglia P, Monetti D, Targhetta R, Bernini G, Lippi A, Nardi M, Acquaviva A, Pannelli F, Tumori R, Sampietro G, Schilirò G, Pulsoni A, Legittimo P, Barone Adesi F, Cavariani F, Belletti I, Troeschel L, Calisti R, Marche C, Silvestri S, Sommani L, Farioli A, Tozzi GA, Terracini B, Paolucci G, Andreuccetti D, Anglesio L, Bertolotti M, Bevitori P, Biancotto R, Biggeri A, Bucci S, Comba P, Crosignani P, d'Amore G, Duglio E, Erna M, Ferrante D, Gelli L, Gilardetti M, Guidotti P, Lombardi M, Loomis D, Magnoni M, Merletti F, Miceli G, Mozzo P, Poggi A, Pons O, Rasulo A, Roletti S, Rosa M, Mestre V, Ru O, Russo G, Sgorbati G, Simonato L, Sivo D, Stievano B, Tofani S, Troti F, Tumino R, Valle M, Vecchia P, Erminio G, Galleni B., PANICO, SALVATORE, Parodi, Stefano, Merlo, Domenico Franco, Ranucci, Alessandra, Miligi, Lucia, Benvenuti, Alessandra, Rondelli, Roberto, Magnani, Corrado, Haupt, Riccardo, [ .., Mattioli, Stefano, ], Parodi, S, Merlo, Df, Ranucci, A, Miligi, L, Benvenuti, A, Rondelli, R, Magnani, C, Haupt, R, Mattioli, S, Salvan, A, Masera, G, Rizzari, C, Bisanti, L, Zambon, P, Greco Veneto, A, Cannizzaro, S, Gafà, L, Luzzatto, Ll, Michelozzi, P, Kirchmayer, U, Cocco, P, Galassi, C, Celentano, E, Guarino, E, Assennato, G, de Nichilo, G, Bocchini, V, Mosciatti, P, Pubblica, S, Minelli, L, Chiavarini, M, Cuttini, M, Casotto, V, Torregrossa, Mv, Valenti, Rm, Forastiere, F, Lagorio, S, Risica, S, Polichetti, A, Bochicchio, F, Nuccetelli, C, Biddau, P, Aricò, M, Desalvo, Gl, Locatelli, F, Pession, A, Varotto, S, Poggi, V, Massaglia, P, Monetti, D, Targhetta, R, Bernini, G, Lippi, A, Nardi, M, Acquaviva, A, Pannelli, F, Tumori, R, Sampietro, G, Schilirò, G, Pulsoni, A, Legittimo, P, Barone Adesi, F, Cavariani, F, Belletti, I, Troeschel, L, Calisti, R, Marche, C, Silvestri, S, Sommani, L, Farioli, A, Tozzi, Ga, Terracini, B, Paolucci, G, Andreuccetti, D, Anglesio, L, Bertolotti, M, Bevitori, P, Biancotto, R, Biggeri, A, Bucci, S, Comba, P, Crosignani, P, D'Amore, G, Duglio, E, Erna, M, Ferrante, D, Gelli, L, Gilardetti, M, Guidotti, P, Lombardi, M, Loomis, D, Magnoni, M, Merletti, F, Miceli, G, Mozzo, P, Panico, Salvatore, Poggi, A, Pons, O, Rasulo, A, Roletti, S, Rosa, M, Mestre, V, Ru, O, Russo, G, Sgorbati, G, Simonato, L, Sivo, D, Stievano, B, Tofani, S, Troti, F, Tumino, R, Valle, M, Vecchia, P, Erminio, G, and Galleni, B.

Subjects
Cancer Research, Pediatrics, medicine.medical_specialty, Epidemiology, Socio-culturale, ELF magnetic fields, ELF magnetic field, Nervous System Malformation, Neuroblastoma, Economica, Work related exposure, parental occupation, male, Pregnancy, Risk Factors, maternal exposure, medicine, Parental occupation, Maternal characteristic, Neurofibromatosis, humans, Neurofibromatosi, neurofibromatosis, business.industry, Risk Factor, Incidence (epidemiology), case-control studies, Ambientale, Congenital malformations, nervous system malformations, Odds ratio, medicine.disease, Pregnancy Complication, Pregnancy Complications, female, Oncology, congenital malformations, maternal characteristics, neuroblastoma, incidence, Etiology, Congenital malformation, Case-Control Studie, business, Human
Abstract

Purpose: Neuroblastoma (NB) is the most common extra-cranial paediatric solid tumour. Incidence peaks in infancy, suggesting a role of in-utero and neonatal exposures but its aetiology is largely unknown. The aim of the present study is to evaluate the association between maternal characteristics and perinatal factors with the risk of NB, using data from the SETIL database. Methods: SETIL is a large Italian population-based case-control study established to evaluate several potential cancer risk factors in 0-10 year olds. Information about maternal characteristics, reproductive history, environmental and occupational exposures during pregnancy, as well as newborns' characteristics were obtained using a structured questionnaire. Extremely low frequency magnetic field (ELF-MF) home exposure was measured. The study included 1044 healthy controls and 153 NB cases, diagnosed between 1998 and 2001. Results: A twofold risk was associated to exposure in pregnancy to chemical products for domestic work and to hair dye. The risk associated with the latter was higher among 0-17 month old children (OR. =. 5.5, 95%CI: 1.0-29.3). Risk was increased for children whose mothers had suffered work related exposure in the preconception period to solvents (OR. =. 2.0 95%CI: 1.0-4.1) and in particular to aromatic hydrocarbons (OR. =. 9.2, 95%CI: 2.4-34.3). No association was observed with ELF-MF exposure. A higher risk was found among children with congenital malformations (OR. =. 4.9, 95%CI: 1.8-13.6) or neurofibromatosis (2 cases and 0 controls, p=. 0.016). Conclusions: Our study suggests maternal exposure to hair dyes and aromatic hydrocarbons plays a role and deserves further investigation. The association with congenital malformations might also be explained by over-diagnosis.External exposure, in particular during and before pregnancy might contribute to NB occurrence.

Published
2014

13. Report sulle modalità organizzative e sugli effetti della somministrazione in regime di Day-Hospital della ciclofosfamide (1 gr/mq) effettuata in 11 centri AIEOP-BFM ALL 2009

Author

Bettini, L., Colombini, A., Spinelli, M., Silvestri, D., Cannata, E., Casini, T., Cesaro, Simone, Giagnuolo, G., Mohamed, S., Melchionda, F., Mosa, C., Pierri, F., Varotto, E., Vinti, L., Conter, V., and Rizzari, C.

Subjects
terapia ambulatoriale, ciclofosfamide, leucemia acuta, terapia ambulatoriale, leucemia acuta, ciclofosfamide
Published
2016

14. 'Identification of a Deletion in Stxbp2 Causative of Familial Hemophagocytic Lymphohistiocytosis Type 5'

Author

M L Coniglio, Arico M, Giglio S, Cetica, E Sieni, Benedetta Ciambotti, Rizzari C, Pantaleo M, Grieve S, Griffiths Gm, and Favre C

Subjects
Genetics, Hemophagocytic lymphohistiocytosis, Perforin, STX11, RNA splicing, biology.protein, medicine, Missense mutation, Familial Hemophagocytic Lymphohistiocytosis, Biology, medicine.disease, Genetic analysis, Gene
Abstract

Hemophagocytic lymphohistiocytosis (HLH) is a rare, life-threatening immune deficiency, characterized by a hyper-inflammatory syndrome. The familial form of HLH (FHL) is caused by mutations in genes associated with lymphocyte granule-mediated cytotoxicity. Mutations in STXBP2 (Sintaxin binding protein 2) gene result in defect of Munc18-2 protein, the causative defect of the subtype defined as FHL5. Functional tests as intracytoplasmic expression of perforin and surface expression of CD107a, help to direct genetic analysis. Different mutations have been described in the FHL-related genes known so far (PRF1, UNC13-D, STX11, STXBP2): missense, nonsense, splicing, regulatory, small deletions/insertions. Recently a pathogenic inversion of 253 KB upstream of the 3’ UNC13D gene has been reported. Here we describe a new deletion causative of FHL5. We confirmed the deletion by Real-Time PCR and by CGHarray. We finally documented by western blot the absence of expression of Munc18-2 protein in our patient. These data shows the need to introduce new diagnostic strategies in order to screen mutations not detected by the methods classically used.

Published
2015

15. Constitutional and somatic deletions of the Williams-Beuren syndrome critical region in Non-Hodgkin Lymphoma

Author

Guenat, D. Quentin, S. Rizzari, C. Lundin, C. Coliva, T. Edery, P. Fryssira, H. Bermont, L. Ferrand, C. Soulier, J. Borg, C. Rohrlich, P.-S.

Subjects
congenital, hereditary, and neonatal diseases and abnormalities, immune system diseases, hemic and lymphatic diseases, cardiovascular diseases
Abstract

Here, we report and investigate the genomic alterations of two novel cases of Non-Hodgkin Lymphoma (NHL) in children with Williams-Beuren syndrome (WBS), a multisystem disorder caused by 7q11.23 hemizygous deletion. Additionally, we report the case of a child with NHL and a somatic 7q11.23 deletion. Although the WBS critical region has not yet been identified as a susceptibility locus in NHL, it harbors a number of genes involved in DNA repair. The high proportion of pediatric NHL reported in WBS is intriguing. Therefore, the role of haploinsufficiency of genes located at 7q11.23 in lymphomagenesis deserves to be investigated. © 2014 Shi et al.

Published
2014

16. Long-term results of the AIEOP-ALL-95 Trial for Childhood Acute Lymphoblastic Leukemia : insight on prognostic value of DNA index in the framework of Berlin-Frnkfurt-Munster based chemotherapy

Author

ARICÒ M, VALSECCHI MG, RIZZARI C, BARISONE E, BIONDI A, LOCATELLI F, LO NIGRO L, LUCANI M, MESSINA C, MICALIZZI C, PARASOLE R, PESSION A, SANTORO N, TESTI AM, SILVESTRI D, BASSO G, MASERA G, CONTER V., CASALE, Fiorina, Aricò, M, Valsecchi, Mg, Rizzari, C, Barisone, E, Biondi, A, Casale, Fiorina, Locatelli, F, LO NIGRO, L, Lucani, M, Messina, C, Micalizzi, C, Parasole, R, Pession, A, Santoro, N, Testi, Am, Silvestri, D, Basso, G, Masera, G, and Conter, V.

Published
2008

17. Risultati a lungo termine ottenuti nei bambini con leucemia linfoblastica acuta ( LLA) ad immunofenotipo T arruolati nei protocolli AIEOP LLA 91 e 95

Author

Rizzari C., Conter V., Valsecchi M.G., Aricò M., Barisone E., Basso G., Biondi A., Casale F., Citterio M., De Rossi G., Lo Nigro L., Locatelli F., Messina C., Micalizzi C., Parasole R., Rondelli R., Santoro N., Silvestri D., Testi A.M., Masera G., PESSION, ANDREA, Rizzari C., Conter V., Valsecchi MG., Aricò M., Barisone E., Basso G., Biondi A., Casale F., Citterio M., De Rossi G., Lo Nigro L., Locatelli F., Messina C., Micalizzi C., Parasole R., Pession A., Rondelli R., Santoro N., Silvestri D., Testi AM., and Masera G.

Published
2007

18. Protocollo AIEOP LAM 2002/01 : risultati preliminari

Author

MASETTI, RICCARDO, Rondelli R., Putti C., Rizzari C., Locatelli F., Santoro N., Luciani M., Menna G., Fagioli F., Lo Nigro L., Micalizzi C., Di Tullio M.T., Basso G., Frascella E., Biondi A., Testi A.M., Zecca M., PESSION, ANDREA, Masetti R., Rondelli R., Putti C., Rizzari C., Locatelli F., Santoro N., Luciani M., Menna G., Fagioli F., Lo Nigro L., Micalizzi C., Di Tullio MT., Basso G., Frascella E., Biondi A., Testi AM., Zecca M., and Pession A.

Published
2007

19. Analisi dei casi di LAM con riarrangiamento della banda 11Q23/gene MLL trattati con il protocollo AIEOP LAM 2002-01:presentazione clinica e risposta al trattamento

Author

Lo Nigro L., Leszl A., Basso G., Putti C., Rizzari C., Locatelli F., Santoro N., Luciani M., Menna G., Fagioli F., Micalizzi C., Di Tullio M.T., Frascella E., Biondi A., Testi A.M., Zecca M., PESSION, ANDREA, Lo Nigro L., Leszl A., Basso G., Putti C., Rizzari C., Locatelli F., Santoro N., Luciani M., Menna G., Fagioli F., Micalizzi C., Di Tullio MT., Frascella E., Biondi A., Testi AM., Zecca M., and Pession A.

Published
2007

21. Il DNA INDEX ha valore prognostico nella LLA del bambino trattata con chemioterapia intensiva tipo bfm.Risultati finali del protocollo AIEOP-LLA-95

Author

Aricò M., Valsecchi M.G., Rizzari C., Barisone E., Biondi A., Casale F., Locatelli F., Lo Nigro L., Baronci C., Messina C., Micalizzi C., Parasole R., Santoro N., Testi A.M., Silvestri D., Basso G., Masera G., Conter V., PESSION, ANDREA, Aricò M., Valsecchi MG., Rizzari C., Barisone E., Biondi A., Casale F., Locatelli F., Lo Nigro L., Baronci C., Messina C., Micalizzi C., Parasole R., Pession A., Santoro N., Testi AM., Silvestri D., Basso G., Masera G., and Conter V.

Published
2007

23. Risultati del protocollo AIEOP-LLA 95 per il trattamento della leucemia linfoblastica acuta(LLA) dell'età pediatrica

Author

Aricò M., Rizzari C., Valsecchi M.G., Barisone E., Basso G., Biondi A., Casale F., de rossi G., Locatelli F., Lo Nigro L., Messina C., Micalizzi C., parasole R., Rondelli R., Sntoro N., Silvestri S., Testi A.M., Masera G., Conter V., PESSION, ANDREA, Aricò M., Rizzari C., Valsecchi MG., Barisone E., Basso G., Biondi A., Casale F., de rossi G., Locatelli F., Lo Nigro L., Messina C., Micalizzi C., parasole R., Pession A., Rondelli R., Sntoro N., Silvestri S., Testi AM., Masera G., and Conter V.

Published
2006

24. Incidenza ed impatto prognostico dei trascritti chimerici MLL-ENL e CALM-AF10 nei bambini affetti da leucemia linfoblastica acuta T-lineage ( LLA -T)arruolati nel protocollo AIEOP -LLA 2000:incidenza ed impattosulla prognosi

Author

Lo Nigro L., Caserta C., Mirabile E., Rossi V., Silvestri D., Spinelli M., Cazzaniga G., Rizzari C., Aricò M., Barisone E., Basso G., Biondi A., Casale F., De Rossi G., Locatelli F., Messina C., Micalizzi C., Santoro N., Testi A.M., Valsecchi M.G., Masera G., Conter V., PESSION, ANDREA, Lo Nigro L., Caserta C., Mirabile E., Rossi V., Silvestri D., Spinelli M., Cazzaniga G., Rizzari C., Aricò M., Barisone E., Basso G., Biondi A., Casale F., De Rossi G., Locatelli F., Messina C., Micalizzi C., Pession A., Santoro N., Testi AM., Valsecchi MG., Masera G., and Conter V.

Published
2006

25. Risultati del protocollo AIEOP LAM 2002/01 per la diagnosi e terapia delle leucemie acute mieloidi pediatriche

Author

PESSION, ANDREA, MASETTI, RICCARDO, Rizzari C., Putti M. C., Santoro N., Luciani M., Menna G., Micalizzi C., Fagioli F., Lo Nigro L., Di Tullio M. T., Basso G., Biondi A., Testi A., Zecca M., Rondelli R., Locatelli F., Pession A., Masetti R., Rizzari C., Putti M.C., Santoro N., Luciani M., Menna G., Micalizzi C., Fagioli F., Lo Nigro L., Di Tullio M.T., Basso G., Biondi A., Testi A., Zecca M., Rondelli R., and Locatelli F.

Published
2006

26. Role of treatment intensification in infants with acute lymphoblastic leukemia: results of two consecutive AIEOP studies

Author

Biondi, A., Rizzari, C., Valsecchi, M. G., Lorenzo, P., Aricò, M., GIUSEPPE BASSO, Locatelli, F., Lo Nigro, L., Rossi, G., Masera, G., Biondi, A, Rizzari, C, Valsecchi, M, De Lorenzo, P, Aricò, M, Basso, G, Locatelli, F, Lo Nigro, L, De Rossi, G, and Masera, G

Subjects
6-Mercaptopurine, Antineoplastic Combined Chemotherapy Protocol, Mercaptopurine, Daunorubicin, Remission Induction, Cytarabine, Hematopoietic Stem Cell Transplantation, Infant, Newborn, Infant, Acute lymphoblastic leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Childhood, Disease-Free Survival, Treatment, Clinical trials, Methotrexate, Vincristine, Antineoplastic Combined Chemotherapy Protocols, Asparaginase, Humans, Prednisone, Cyclophosphamide, Human
Abstract

Fifty-two infants with acute lymphoblastic leukemia (ALL) enrolled in the AIEOP ALL-91 and ALL-95 studies were treated with the intermediate or high risk protocols according to their presenting features and early response to treatment. The 5-year event-free survival was 33.3% (95% CI 12.1-54.5), 53.5% (95% CI 35.7-71.3) and 45.0% (95% CI 31.3-58.7) in the ALL-91 and ALL-95 studies and in the overall cohort, respectively. In the ALL-95 high-risk group (BFM therapy intensified by three blocks and double protocol II) nine of 17 patients treated with chemotherapy only and three of four transplanted patients were alive and in complete remission. The corresponding figures for patients treated in the ALL-91 high-risk protocol (reduced induction and nine blocks) were one of seven patients treated with chemotherapy only and none of two who were transplanted.

Published
2005

27. Effect of protracted high-dose L-asparaginase given as a second exposure in a Berlin-Frankfurt-Münster-based treatment: results of the randomized 9102 intermediate-risk childhood acute lymphoblastic leukemia study--a report from the Associazione Italiana Ematologia Oncologia Pediatrica

Author

Rizzari, C, Valsecchi, Mg, Aricò, M, Conter, V, Testi, A, Barisone, E, Casale, F, Lo Nigro, L, Rondelli, R, Basso, Giuseppe, Santoro, N, Masera, G, Associazione Italiano Ematologia Oncologia Pediatrica, Rizzari, C, Valsecchi, M, Aricò, M, Conter, V, Testi, A, Barisone, E, Casale, F, Lo Nigro, L, Rondelli, R, Basso, G, Santoro, N, Masera, G, Valsecchi, Mg, Arico, M, Casale, Fiorina, LO NIGRO, L, and ASSOCIAZIONE ITALIANO EMATOLOGIA ONCOLOGIA, Pediatrica

Subjects
Male, Cancer Research, medicine.medical_specialty, Asparaginase, Adolescent, Context (language use), Antineoplastic Agents, Injections, Intramuscular, Disease-Free Survival, law.invention, Antineoplastic Agent, chemistry.chemical_compound, Randomized controlled trial, law, Internal medicine, Acute lymphocytic leukemia, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Child, Childhood Acute Lymphoblastic Leukemia, Antineoplastic Combined Chemotherapy Protocol, business.industry, Standard treatment, Therapeutic effect, Infant, Newborn, Infant, Precursor Cell Lymphoblastic Leukemia-Lymphoma, medicine.disease, Chemotherapy regimen, Surgery, Treatment Outcome, Oncology, chemistry, Child, Preschool, Female, business, Human
Abstract

PURPOSE: To assess in a randomized study the therapeutic effect of the addition of high-dose l-asparaginase (HD ASP) in the context of a Berlin-Frankfurt-Münster (BFM)–based chemotherapy regimen for intermediate risk (IR) childhood acute lymphoblastic leukemia (ALL). PATIENTS AND METHODS: From March 1991 to April 1995, a total of 705 patients, with 59% of the cohort of patients fewer than 15 years old, with newly diagnosed non-B ALL, enrolled onto the Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP) ALL-91 study, were assigned to the IR group. Patients in remission at the beginning of the reinduction phase were randomized either to the standard treatment (SD ASP arm) or the experimental treatment (HD ASP arm; weekly intramuscular administration of HD ASP 25,000 IU/m2 repeated for a total of 20 weeks). Most of the patients (90%) were treated with Erwinia chrysanthemi l-asparaginase product. RESULTS: Among the 610 patients randomized to the SD ASP arm (n = 322) or to the HD ASP arm (n = 288), relapse occurred at a median time of 24 months after randomization in 76 (24%) and in 64 children (22%), respectively. Most of the relapses occurred in the marrow (100 isolated, 21 combined). There was no significant difference between the disease-free survival in the two treatment arms (P = .64), with estimated values at 7 years from randomization of 72.4% (SE 3.1) v 75.7% (SE 2.6) in the SD ASP and HD ASP arms, respectively. CONCLUSION: No advantage was observed for IR ALL children treated with BFM-based intensive chemotherapy who received protracted E chrysanthemi HD ASP during reinduction and the early continuation phase.

Published
2001

37. Valutazione della correlazione prognostica tra elevata infiltrazione blastica midollare (>25%) al giorno +15 della fase IA, risposta al prednisone e malattia residua minima in pazienti trattati con il protocollo AIEOP LLA 2000

Author

Rizzari, C, Conter, V, Cazzaniga, G, Valsecchi, Mg, Silvestri, D, Aricò, M, Barisone, E, Casale, F, De Rossi, G, Locatelli, F, Lo Nigro, L, Messina, C, Micalizzi, C, Pession, A, Parasole, R, Rondelli, R, Santoro, N, Testi, Anna Maria, Basso, G, Biondi, A, and Masera, G.

Published
2005

38. Efficacia dell'uso del methotrexate ad alte dosi (HD-MTX 2 g/mq) associato a terapia intratecale protratta con methotrexate, nella prevenzione della recidiva al sistema nervoso centrale in pazienti non sottoposti a radioterapia craniale: esperienza del protocollo AIEOP LLA 95

Author

Conter, V, Rizzari, C, Valsecchi, Mg, Silvestri, D, Aricò, M, Barisone, E, Casale, F, De Rossi, G, Locatelli, F, Lo Nigro, L, Messina, C, Micalizzi, C, Pession, A, Parasole, R, Rondelli, R, Santoro, N, Testi, Anna Maria, Jankovic, M, Basso, G, Biondi, A, and Masera, G.

Published
2005

41. Protocollo AIEOP LAM 2002/01: risultati preliminari

Author

Pession, A, Masetti, R, Putti, C, Rizzari, C, Locatelli, F, Santoro, N, Luciani, M, Menna, G, Fagioli, F, Lo Nigro, L, Micalizzi, C, Casale, F, Testi, Anna Maria, Zecca, M, Rondelli, R, Biondi, A, and Basso, G.

Published
2005

42. Clinical features of childhood acute myeloid leukaemia with specific gene rearrangements [1]

Author

Frascella, Emanuela, Rondelli, R., Pigazzi, M., Zampieron, C., Fagioli, F., Favre, C., Lippi, A. A., Locatelli, F., Luciani, M., Menna, G., Micalizzi, C., Rizzari, C., Testi, A. M., Pession, A., and Basso, G.

Subjects
Adult, Myeloid, Male, Gene Rearrangement, Molecular Epidemiology, Cancer Research, Leukemia, Adolescent, Acute Disease, Child, Child, Preschool, Cytogenetic Analysis, Female, Humans, Infant, Italy, Leukemia, Myeloid, Survival Analysis, Hematology, Oncology, Preschool
Published
2004

Catalog

Books, media, physical & digital resources
See catalog results